BioSpace News Archive

ANI Pharmaceuticals, Inc. announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows.

AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.

Willow Biosciences Inc. announces that having completed its transition to the San Francisco Bay Area and the commercial focus on its BioOxi platform, it has engaged an advisor to assist the Company with a review of opportunities to enhance shareholder value and unlock its intellectual property portfolio.~

Abata Therapeutics today announced its second development candidate, ABA-201, which has the potential to be a disease-modifying Treg cell therapy for patients with type 1 diabetes (T1D) who have remaining beta (β) cell function.

Jaguar Health, Inc., a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal prescription medicines, announced it has engaged B2i Digital to execute an innovative digital investor engagement and awareness program.

Can-Fite BioPharma Ltd. announced it plans to develop its lead drug candidate, Piclidenoson, for the treatment of Lowe Syndrome based on recent efficacy findings by Dr. Antonella De Matteis, Professor of Biology, Department of Molecular Medicine and Medical Biotechnology at the University of Naples Federico II, and Program Coordinator of the Cell Biology and Disease Mechanisms at The Telethon Institute of Genetics and Medicine in Italy.

Aprea Therapeutics, Inc., a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, announced it has appointed Dr. Jean-Pierre Bizzari to its Board of Directors and is naming Dr. Richard Peters as its new Chairman of the Board.

Intelligent Bio Solutions Inc., a medical technology company delivering intelligent, rapid, non-invasive testing solutions, announced its financial results for its fiscal fourth quarter and full-year ended June 30, 2023, and provided a business update.

LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023.

Collegium Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration has granted New Patient Population exclusivity for Nucynta®, an immediate release formulation of tapentadol.